What is Miroculus?
Founded in 2014, Miroculus has established itself as a leader in the miniaturization and automation of genomic protocols. The company's core technology utilizes digital microfluidics to streamline labor-intensive processes, including Next-Generation Sequencing (NGS) library preparation, synthetic biology, cell editing, and combinatorial chemistry. By integrating these complex procedures into a compact, user-friendly system, Miroculus effectively reduces the barrier to entry for high-throughput genomic analysis. This technological advancement is particularly vital for research institutions and clinical laboratories seeking to enhance precision while minimizing human error and reagent consumption in their daily operations.
How much funding has Miroculus raised?
Miroculus has raised a total of $48.2M across 3 funding rounds:
Angel/Seed
$2.8M
Debt
$350K
Series B
$45M
Angel/Seed (2015): $2.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Series B (2021): $45M supported by Cota Capital and Section 32
Key Investors in Miroculus
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise.
Section 32
S32 | Venture Beyond is a venture capital firm founded by Bill Maris that targets innovative startups and emerging technologies at the forefront of scientific and technological advancement.
Undisclosed Investors
What's next for Miroculus?
With the recent capital injection, Miroculus is poised to expand its operational footprint and deepen its penetration into the enterprise biotech sector. The strategic focus will likely center on scaling the manufacturing of its microfluidic systems and broadening the application library to support emerging fields such as personalized medicine and advanced cell therapy. As the company transitions into this next phase of growth, the emphasis will remain on maintaining its competitive edge in digital microfluidics while fostering strategic partnerships that integrate its hardware into broader laboratory ecosystems. The firm's ability to maintain its technological lead will be the primary driver of its long-term valuation and market influence.
See full Miroculus company page
